Form 4: enGene Holdings Director Acquires Options
SEC Form 4 Filing
Director Gerald A. Brunk acquired options to purchase 20,000 common shares of enGene Holdings Inc.
Summary
- On June 15, 2024, Gerald A. Brunk, a director of enGene Holdings Inc., acquired options to purchase 20,000 common shares.
- The options have an exercise price of $9.
- The options vest on the earlier of May 15, 2025, or the 2025 Annual Meeting of Shareholders and expire on June 15, 2034.
- These options are held by Mr. Brunk for the benefit of Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P., and Merck Lumira Biosciences Fund (Quebec), L.P.
- Mr. Brunk disclaims beneficial ownership of these securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
This filing reflects insider activity, which is closely monitored by investors for signals about a company's prospects. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date vesting commenced for the options. |
| 06/15/2024 | Date of transaction: Director acquired options to purchase shares. |
| 06/15/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.